Claims
- 1. A method for diagnosis of CMV, said method comprising administering to a subject having CMV, an image-generating amount of a compound having the formula:
- 2. A method in accordance with claim 1, wherein Ar is substituted phenyl.
- 3. A method in accordance with claim 1, wherein Ar is substituted phenyl and NHet is selected from the group consisting of substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperazinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl and substituted or unsubstituted piperidyl.
- 4. A method in accordance with claim 1, wherein said compound has the formula:
- 5. A method in accordance with claim 1, wherein said compound is labeled with a radioisotope selected from the group consisting of 18F, 75Br, 123I and 125I.
- 6. A method in accordance with claim 4, wherein n is 1; R11 is H; R12, R13 and R14 are each independently selected from the group consisting of H, hydroxy, halogen, (C1-C4)alkyl and (C1-C4)alkoxy; and R15 is (C1-C4)alkyl.
- 7. A method in accordance with claim 4, wherein said compound is IBZM.
- 8. A method in accordance with claim 4, wherein said compound is 123I-IBZM.
- 9. A method for treating CMV in a human, comprising administering an effective amount of a compound which blocks the binding of a chemokine to US28 or a US28 fragment.
- 10. A method in accordance with claim 9, wherein said compound has the formula:
- 11. A method in accordance with claim 10, wherein Ar is substituted phenyl.
- 12. A method in accordance with claim 10, wherein Ar is substituted phenyl and NHet is selected from the group consisting of substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperazinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl and substituted or unsubstituted piperidyl.
- 13. A method in accordance with claim 10, wherein said compound has the formula:
- 14. A method in accordance with claim 13, wherein n is 1, R11 is H, R15 is (C1-C4)alkyl, and R12, R13 and R14 are all other than H.
- 15. A method in accordance with claim 13, wherein n is 1; R11 is H; R12, R13 and R14 are each independently selected from the group consisting of H, hydroxy, halogen, (C1-C4)alkyl and (C1-C4)alkoxy; and R15 is (C1-C4)alkyl.
- 16. A method for reducing cell motility in a CMV-infected cell, said method comprising contacting said CMV-infected cell with a motility-reducing amount of a compound that inhibits chemokine binding to US28 on the surface of said infected cell.
- 17. A method in accordance with claim 16, wherein said chemokine is a member selected from the group consisting of fractalkine, MIP-1α, MIP-1β, MCP-1 and RANTES.
- 18. A method in accordance with claim 16, wherein said chemokine is fractalkine.
- 19. A method in accordance with claim 16, wherein said compound has the formula:
- 20. A method in accordance with claim 19, wherein Ar is substituted phenyl.
- 21. A method in accordance with claim 19, wherein Ar is substituted phenyl, and NHet is selected from the group consisting of substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperazinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl and substituted or unsubstituted piperidyl.
- 22. A method in accordance with claim 16, wherein said compound has the formula:
- 23. A method in accordance with claim 22, wherein n is 1, R11 is H, R15 is (C1-C4)alkyl, and R12, R13 and R14 are all other than H.
- 24. A method in accordance with claim 22, wherein n is 1; R11 is H; R12, R13 and R14 are each independently selected from the group consisting of H, hydroxy, halogen, (C1-C4)alkyl and (C1-C4)alkoxy; and R15 is (C1-C4)alkyl.
- 25. A method in accordance with claim 22, wherein said compound is IBZM or a pharmaceutically acceptable salt thereof.
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Patent Application Serial No. 60/229,191, filed Aug. 30, 2000, the disclosure of which is incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60229191 |
Aug 2000 |
US |